MDGL

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc. (“Madrigal”) (NASDAQ: MDGL) on behalf of investors who purchased or acquired Madrigal securities and experienced significant financial losses.Whistleblower Complaint filed against MadrigalOn November 3, 2026, Madrigal disclosed in its quarterly report that.

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 3, 2026 disclosure regarding Madrigal Pharmaceuticals,.

New York, New York--(Newsfile Corp. - November 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

CONSHOHOCKEN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced results from multiple real-world studies of Rezdiffra presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place Nov. 5–9 in Denver.

Madrigal Pharmaceuticals delivered another earnings beat, with Q3 net sales up 50% YoY, and Rezdiffra's blockbuster status confirmed. Despite exceeding expectations, MDGL shares fell ~8% post-earnings, potentially due to a whistleblower disclosure. Rezdiffra has only ~10% market penetration in a rapidly expanding MASH market, with significant growth potential and patent protection into 2045.

Madrigal Pharmaceuticals NASDAQ: MDGL reported third-quarter 2026 net sales of $431.3 million for its MASH treatment Rezdiffra, up 50% from the prior-year period, as the company said it continued to add patients and expand its prescriber base. Year-to-date net sales reached $1.1 billion, and the company reported its first profitable quarter.

Madrigal (MDGL) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of a loss of $1.09 per share. This compares to a loss of $5.08 per share a year ago.

CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial results and provides corporate updates.

Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.